---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053533"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:46:44.647077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q1 2024 revenue up 55% YoY to $55.9M; net loss narrows to $32.9M

## Summary
- Net loss of $32.9M ($0.33 per share) vs $76.7M loss ($0.81 per share) in Q1 2023.
- Roxadustat China net sales by FibroGen and JDE totaled $79.4M, up 24% YoY on 39% volume growth.
- Topline data for pamrevlumab in metastatic pancreatic cancer expected mid-2024; LAPIS Phase 3 data in 3Q 2024.
- Phase 1 FG-3246 (CD46 ADC) in mCRPC showed median rPFS of 8.7 months; 20% partial response rate.
- Cash and receivables $214.7M; runway into 2026; FY 2024 roxadustat revenue guidance reaffirmed $120-135M.

## SEC filing metadata
- accession: 0000950170-24-053533
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024053533/0000950170-24-053533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024053533/fgen-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053533
- JSON: https://secwatch.observer/filing/0000950170-24-053533.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.